Aptevo Therapeutics Inc. (NASDAQ:APVO)’s share price rose 15.4% during trading on Tuesday . The stock traded as high as $3.70 and last traded at $3.45. Approximately 1,963,500 shares traded hands during trading, an increase of 478% from the average daily volume of 339,776 shares. The stock had previously closed at $2.99.
APVO has been the subject of several recent research reports. ValuEngine raised Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, October 12th. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $6.00 price target on shares of Aptevo Therapeutics in a research report on Thursday, October 5th.
The company has a quick ratio of 7.67, a current ratio of 7.76 and a debt-to-equity ratio of 0.19.
Institutional investors and hedge funds have recently bought and sold shares of the company. Spark Investment Management LLC raised its position in shares of Aptevo Therapeutics by 167.4% in the 2nd quarter. Spark Investment Management LLC now owns 61,500 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 38,500 shares during the last quarter. Legal & General Group Plc raised its position in shares of Aptevo Therapeutics by 11,751.3% in the 2nd quarter. Legal & General Group Plc now owns 393,701 shares of the biotechnology company’s stock worth $815,000 after purchasing an additional 390,379 shares during the last quarter. Precept Management LLC purchased a new position in shares of Aptevo Therapeutics in the 2nd quarter worth about $1,210,000. Finally, Dimensional Fund Advisors LP raised its position in shares of Aptevo Therapeutics by 8.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,056,729 shares of the biotechnology company’s stock worth $2,187,000 after purchasing an additional 78,109 shares during the last quarter. 32.22% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This report was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://www.com-unik.info/2017/12/05/aptevo-therapeutics-apvo-stock-price-up-15-4.html.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company’s technology is the ADAPTIR (modular protein technology) platform.
What are top analysts saying about Aptevo Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aptevo Therapeutics Inc. and related companies.